Palvella COO disposes $507,610 in shares as company advances pipeline and IP
Kathleen Goin, chief operating officer of Palvella Therapeutics, sold $507,610 worth of company stock on March 18, 2026. The transaction was carried out under a Rule 10b5-1 plan and coincided with recent company milestones including a $230 million public offering, issuance of a European patent for QTORIN gel, and the launch of a disease-awareness c…